Benefits and risks of using gelatin solution as a plasma expander for perioperative and critically ill patients: a meta-analysis SUMMARY This meta-analysis aimed to evaluate the benefits and risks of gelatin solutions compared to other intravenous fluids for patients in perioperative and critical care settings. Of the 66 studies identified from MEDLINE and EMBASE databases, 30 randomised controlled trials involving 2709 patients met the inclusion criteria and were subject to meta-analysis. The risk of mortality (odds ratio 1.03, 95% confidence interval 0.80 to 1.32) and amount of blood loss (weighted-mean-difference 7.56 ml, 95% confidence interval 18.75 to 33.87) were not significantly different between patients who were treated with gelatin solutions and other types of intravenous fluids. When compared to starches, gelatin solutions were associated with a lower risk of acute renal failure (odds ratio 0.43, 95% confidence interval 0.20 to 0.92; P=0.03). When gelatin solutions were compared to isotonic albumin, patients who were treated with gelatin solutions required a small, but significantly greater amount of blood transfusion (weighted-mean-difference 180 ml, 95% confidence interval 8.1 to 353.6; P=0.04). These findings suggest that using gelatin solutions is associated with a lower risk of acute renal failure compared to older starches. Using gelatin as a plasma expander appears to have no significant advantages over crystalloids or isotonic albumin on mortality and may have a slightly higher risk of requiring allogeneic blood transfusion in perioperative and critically ill patients. An adequately powered randomised controlled trial with economic analysis is needed before gelatin solution can be recommended as a routine plasma expander for patients undergoing major surgery or who are critically ill.
The importance of intravenous fluids in the resuscitation of hypotensive patients was first recognised over a hundred years ago. Debate surrounding what type of fluid to use has continued for nearly as long and remains unresolved. Although colloid solutions may improve haemodynamic responses better than crystalloid solutions, a recent large randomised controlled trial (RCT) of using isotonic albumin in critically ill patients failed to demonstrate significant improvement in patient outcomes compared to isotonic saline solution 1 . Furthermore, whether one colloid solution is superior to the others remains uncertain.
Gelatin used for intravenous infusion is usually extracted from bovine collagen. Its use in resuscitation was first described in 1915, but it was not until the Second World War that interest in using gelatin solution as a plasma expander was renewed and further trials showed that gelatin solution was effective in increasing plasma volume for patients in shock 2, 3 . The two common forms of gelatin solutions in clinical use today are urea-linked gelatin or polygeline (Haemaccel ® , Piramal Healthcare Ltd, Mumbai, Maharashtra, India) and succinylated gelatin (Gelofusine ® , B. Braun Melsungen AG, Melsungen, Germany). Both intravenous gelatinbased solutions have a plasma half-life of around three hours, and are relatively cheap and easy to store.
Anaphylactic and anaphylactoid reactions, with a quoted incidence of 0.038%, appear to be the most common serious complication of gelatin solutions 4 , but concerns about their effects on coagulation have also been raised 5, 6 . We hypothesised that intravenous gelatin is safe as a plasma expander and conducted a meta-analysis to assess whether gelatin solutions would result in excess mortality, a higher risk of bleeding requiring transfusion or higher rates of acute renal failure compared to a) intravenous crystalloid, b) starch, c) isotonic albumin solution or d) dextran in perioperative and critical care settings.
METHODS

Literature search
Two authors independently searched the biomedical online database MEDLINE ® , National Library of Medicine, Bethesda, Maryland, USA, (1948 to December 2010) and EMBASE ® , Reed Elsevier, London, UK, (1980 to December 2010) for relevant RCTs comparing gelatin solutions with a) crystalloids, b) starch, c) isotonic albumin or d) dextran. The following Medical Subject Headings were used: "polygeline" or "gelatine" searched for either alone or in combination with "shock", "hemorrhage", "fluid therapy" or "sepsis". We also searched for the terms "haemaccel", "gelofusine" and "major surgery". Full text articles were obtained for any comparative studies we identified which used a gelatin-based solution as a plasma expander in humans. There were no language restrictions. Non-English articles were translated by speakers fluent in the language and with a medical background. Both paediatric and adult studies were included. Reference lists of included trials were also searched for relevant articles. Studies which were not randomised (e.g. cohort studies), allowed crossover, used blood products as the comparator fluid or were performed in vitro or in healthy volunteers, were excluded.
Data extraction
The primary outcome of this review was hospital mortality (or 28-day mortality when hospital mortality was not available). Other outcomes were incidence of acute renal failure (as defined by the original study), total blood loss during the study period, proportion of patients requiring allogeneic blood transfusion, volume of blood transfused (assuming one unit= 300 ml), incidence of allergic reactions and length of hospital stay. All outcomes and definitions were predetermined prior to the commencement of data extraction. Two authors independently extracted the data using a standardised data abstraction form and we clarified any missing or ambiguous data of the included studies by contacting relevant corresponding authors. In one paper, relevant data were extracted from graphs, as we could not ascertain the data from the tables or from the authors of the study 7 . A number of studies were found to describe the same study population -in these cases we combined all the published manuscripts derived from the same cohort of patients as one study [8] [9] [10] [11] 29, 30 . Any discrepancies in data extracted were resolved by consensus amongst the three investigators.
Statistical analysis
Continuous data were described as mean and SD. If only median and range were reported, the median was used to approximate the mean, and range divided by four was used to estimate SD. Data entry was performed by one of the investigators and values subsequently checked for transcription errors by a second investigator. Analyses were performed using the software Review Manager ® version 4.3.2 (Cochrane Collaboration.12, Nordic Cochrane Centre, Copenhagen, Denmark). The analyses were initially performed using a fixed-effect model and, if the results were significant, repeated with a randomeffects model to confirm robustness of the results. Summary effects were expressed as odds ratios (OR) with 95% confidence intervals (CI) for dichotomous variables and weighted-mean-differences (WMD) with 95% CIs for continuous variables, stratified by the type of comparator fluid or type of starch used ('old' vs newer 6% hydroxyethyl starch 130/0.4).
The presence of heterogeneity was assessed by the I 2 statistic and an I 2 >40% was taken as significant heterogeneity in this study. A restricted analysis on the mortality effect of gelatin solutions in cardiac surgical patients alone or studies that had adequate allocation concealment and double-blinding was also performed. Using mortality or proportion of patients requiring allogeneic blood transfusion as an end-point, two funnel plots were used to assess the risk of publication bias. A P value of less than 0.05 was considered to be significant.
RESULTS
Study selection
Of the 66 studies on gelatin solutions identified from the literature search, 30 studies met the inclusion criteria [7] [8] [9] and were subject to metaanalysis ( Figure 1 ). Thirteen studies recruited patients undergoing elective cardiac surgery, nine studies recruited patients undergoing orthopaedic or major abdominal surgery, one study recruited patients after trauma, one study recruited paediatric patients with septic shock and the remaining six studies recruited critically ill adult patients in the intensive care unit. A total of six studies had adequate allocation concealment, three studies were double-blinded, but none had both adequate allocation concealment and double-blinding. The characteristics of the included studies are described in Table 1 .
Effect of using gelatin on risk of mortality A total of 14 trials involving 1788 patients reported data on mortality. Using gelatin as a plasma expander was not associated with an increase in mortality when compared to other types of intravenous fluids when all strata of different types of alternative fluids were pooled together (OR 1.03, 95% CI 0.80 to 1.32) ( Figure 2) . The effect of gelatin on mortality was not different when compared to only a) crystalloids (OR 1.22, 95% CI 0.75 to 1.99), b) hydroxyethyl starches (OR 0.91, 95% CI 0.59 to 1.41), or c) albumin (OR 1.01, 95% CI 0.67 to 1.51). There was no significant heterogeneity between the pooled trials (I 2 =0%).
Effect of gelatin on risk of acute renal failure
A total of five trials involving 431 patients reported data on incidence of acute renal failure. Overall there was no significant difference between gelatin and alterative intravenous fluids on the risk of acute renal failure when all strata of different alternative fluids were pooled together (OR 0.74, 95% CI 0.42 to 1.29) ( Figure 3 ), but significant heterogeneity between the included trials was observed (I 2 =55.4%). When compared to intravenous hydroxyethyl starches, using gelatin solutions was associated with a lower risk of acute renal failure (OR 0.43, 95% CI 0.20 to 0.92), primarily due to the data from one study using older starch in septic intensive care unit patients 27 . There were no significant differences in the risk of acute renal failure when gelatin was compared to crystalloids (OR 0.73, 95% CI 0.14 to 3.89) or isotonic albumin (OR 2.20, 95%CI 0.71 to 6.81).
Effect of gelatin on transfusion requirement
A total of 11 studies comprising of 796 patients reported on the amount of allogeneic blood transfusion during the study period. There was no significant difference between gelatin solutions and other intravenous fluids when all strata of different alternative fluids were pooled together (WMD 0.0 ml, 95% CI -0.51 to 0.51; I 2 =28.6%) (Figure 4 ). There was, however, a significant difference in the amount of allogeneic blood transfusion in subgroup analysis when gelatin was compared to isotonic albumin solution alone (WMD 180 ml, 95% CI 8.1 to 353.6). Transfusion requirement was not significantly different after using gelatin as a plasma expander compared to crystalloids (-24 ml, 95% CI -91.2 to 42.2), starch (0 ml, 95% CI -0.51 to 0.51), or dextran (100 ml, 95% CI -326.8 to 526.8).
Effect of gelatin on risk of requiring allogeneic blood transfusion and blood loss
Although the proportion of patients requiring allogeneic transfusion after receiving gelatin solutions was not significantly different from patients who had received other types of intravenous fluids when all strata of different alternative fluids were pooled together (OR 1.04, 95% CI 0.77 to 1.40), more patients in the gelatin group required allogeneic transfusion compared to patients given crystalloids (OR 1.67, 95% CI 1.02 to 2.73), explaining the heterogeneity between the strata of trials (I 2 =42.3%) ( Figure 5 ). When this subgroup analysis was repeated with a random-effects model this difference did not reach statistical significance (OR 1.58, 95% CI 0.95 to 2.61). There was no difference seen between gelatin vs starch (OR 0.79, 95% CI 0.53 to 1.17), or gelatin vs isotonic albumin (OR 0.5, 95% CI 0.1 to 2.63).
Nineteen trials involving 1252 patients reported total volume of blood loss during the study period. There was no significant difference in blood loss between those who were treated with gelatin solutions and other intravenous fluids, when all strata of different alternative fluids were pooled together (WMD 7.56 ml, 95% CI -18.75 to 33.87 Figure 6 : Total blood loss. WMD=weighted-mean-differences, CI=confidence interval.
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Other outcomes
Three studies reported hospital length of stay of 262 patients. No significant difference between gelatin solutions and other intravenous fluids was found (WMD 0.27 days, 95% CI -0.61 to 1.15; I 2 =0%). Five studies reported the incidence of allergic reactions and none of the 229 patients randomised to receive gelatin solution experienced any adverse reactions.
Sensitivity analyses
A reduced risk of acute renal failure after gelatin solutions compared to starches persisted, but the difference in proportion of patients requiring allogeneic transfusion became insignificant (OR 1.58, 95% CI 0.95 to 2.61) when the data were analysed by a random-effects model.
In the restricted analyses, the mortality of cardiac surgical patients was not significantly different between patients who were treated with gelatin solutions and other types of intravenous solutions. Because no studies had both adequate allocation concealment and double-blinding, a restricted analysis on higher quality studies was not possible.
Publication bias
Using mortality and the proportion of patients requiring allogeneic blood transfusion as end-points, the funnel plots did not suggest significant publication bias favouring gelatin solutions in small studies (Figures 7 and 8 ).
DISCUSSION
Although using colloid solution has a theoretical advantage of generating a greater intravascular expansion than crystalloid solutions 41 , it also has the disadvantages of greater cost and the risk of adverse reactions and potential adverse effects on the coagulation and renal systems. Our results showed that using gelatin solution as a plasma expander was not associated with either a beneficial or an adverse effect on mortality compared to other types of intravenous fluid, including crystalloids, starch or isotonic albumin. Gelatin was however, associated with a lower risk of acute renal failure compared to older starch. When compared to isotonic albumin and crystalloids, gelatin appeared to be associated with a larger amount of transfusion and a higher risk of requiring allogeneic blood transfusion, respectively.
The optimal choice of intravenous fluid replacement therapy for perioperative and critically ill patients remains highly controversial, especially after many studies on colloid solutions published by Boldt were retracted recently. After excluding all the studies that were retracted, our results showed that using gelatin solution as a plasma expander was associated with a lower risk of acute renal failure compared to hydroxyethyl starches (OR 0.43, 95% CI 0.20 to 0.92) ( Figure 3 ). However, this subgroup analysis consisted of data from only two studies with a total of 219 patients and cases of acute renal failure occurred predominantly in the study comparing 'older' starch with gelatin in critically ill patients with sepsis 27 . No case of acute renal failure was observed in a small study (n=90) comparing gelatin to the 'newer' starch 25 . As such, gelatin may still be preferable to starch, especially in patients who are at risk of developing acute renal failure, at least until adequately powered RCTs have confirmed the safety of newer starches.
The association between the use of gelatin and a higher risk of requiring allogeneic transfusion compared to crystalloids (OR 1.67, 95% CI 1.02 to 2.73) ( Figure 5 ), or larger transfusion requirement compared to albumin (WMD 180 ml, 95% CI 8.1 to 353.6) ( Figure 4 ) requires careful consideration. On the one hand, a number of other studies have demonstrated that gelatin solution can reduce maximum in vitro clot strength, as measured by thrombelastography and by fibrin polymerisati on 8, 9, 18, 19, 22, 42 . On the other hand, we did not find an association between gelatin and total blood loss compared to other intravenous fluids (WMD 7 ml, 95% CI -18.7 to 33.8) ( Figure 6 ). Furthermore, the association between risk of requiring allogeneic blood transfusion and gelatin, when compared to crystalloids, became statistically insignificant when analysed by a random-effects model. This suggests that the adverse association between transfusion and gelatin may well be spurious. However, given the known risks associated with blood transfusion and the vast number of perioperative and critically ill patients who are treated with gelatin solutions on a daily basis, it is important for us to confirm the safety of gelatin with an adequately powered RCT. Costeffective analysis should also be considered in such RCTs because gelatin solutions are more expensive than crystalloid solutions.
Our systematic review has some limitations. First, the majority of studies identified involved fewer than 100 patients and only two studies recruited more than 200 participants. The sample size in each stratum of comparison between gelatin and other types of intravenous fluid was also relatively small; hence the results were imprecise and prone to type II errors. The sample size of this meta-analysis on the mortality outcome (n=1900 patients) has a power of only 80% to detect a 5% increase in mortality compared to other types of intravenous fluid if the mortality rate of the latter group was 13%. Second, the patients included in the pooled trials were heterogeneous, ranging from major elective surgery (e.g. cardiac surgery, orthopaedic surgery or major gastrointestinal surgery) to critically ill patients with sepsis and hypovolaemia. Finally, most of the studies were designed to examine short-term outcomes only. The quality of the published studies on gelatin solutions was also unsatisfactory, with no study having both adequate allocation concealment and doubleblinding. This could have introduced a potential bias due to the investigators' prior beliefs on the benefits and risks of gelatin solutions.
CONCLUSION
The current limited evidence suggests that using gelatin solutions compared to other fluids is not associated with either a beneficial or an adverse effect on mortality in critically ill patients. Moreover, using gelatin solutions as a plasma expander appears to have no significant advantage over crystalloids or isotonic albumin. However, they appear to be associated with a lower risk of acute renal failure compared to older starches. On the other hand, they may be associated with a slightly higher risk of requiring allogeneic blood transfusion for perioperative and critically ill patients. An adequately powered RCT with economic analysis is needed before gelatin solutions can be recommended as a routine plasma expander for patients undergoing major surgery or who are critically ill.
